Monopar Therapeutics Inc.
MNPR
$80.13
-$2.43-2.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 128.69% | 108.42% | 31.22% | -21.20% | -10.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.81% | 86.94% | 479.22% | -23.77% | -23.17% |
| Operating Income | -80.81% | -86.94% | -479.22% | 23.77% | 23.17% |
| Income Before Tax | -43.04% | -59.94% | -502.33% | 33.24% | 22.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.04% | -59.94% | -502.33% | 33.24% | 22.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.04% | -59.94% | -502.33% | 33.24% | 22.03% |
| EBIT | -80.81% | -86.94% | -479.22% | 23.77% | 23.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.41% | 26.84% | -259.71% | 46.45% | 40.26% |
| Normalized Basic EPS | 28.40% | 26.85% | -259.71% | 46.44% | 40.27% |
| EPS Diluted | 28.41% | 26.84% | -259.71% | 46.45% | 40.26% |
| Normalized Diluted EPS | 28.40% | 26.85% | -259.71% | 46.44% | 40.27% |
| Average Basic Shares Outstanding | 99.78% | 118.63% | 67.44% | 24.67% | 30.51% |
| Average Diluted Shares Outstanding | 99.78% | 118.63% | 67.44% | 24.67% | 30.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |